Our science

Tumor
plasticity : a key driver of patient's relapse

Adapted from Hallmarks of cancer: New dimension*

icon key

Unlocking phenotypic plasticity

Cancer is a moving target causing:

  • Resistance mechanism
  • Immune escape
  • Relapsing process

Current treatment must be combined to be efficient

Lack of antigenicity

With limited and static targets

Lack of immunocenicity

With hidden targets to the immune system
Brenus Pharma:
the missing link ?

Brenus Pharma develops a next gen immun therapeutic based on adaptive & multispecific targets to educate the immune system to anticipate tumor plasticity & treatment resistance.

Engage with us ina change of paradigm

  • Arrow logo brenus pharma

    Efficient technology

    Anticipates risks of tumor escape
    Answers huge unmet need in sold tumors

  • Arrow logo brenus pharma

    Derisked approach

    2nd generation of innovative immuno-oncology
    FDA Pre-IND passed
    Top scientific leaders on board

  • Arrow logo brenus pharma

    Limitless potential

    IP by design-platform strategy
    Tailored first-in-class drugs design
    Dynamic immuno-oncology market

Stay tuned